Gross P A, Hermogenes A W, Sacks H S, Lau J, Levandowski R A
Department of Internal Medicine, Hackensack Medical Center, NJ 07601, USA.
Ann Intern Med. 1995 Oct 1;123(7):518-27. doi: 10.7326/0003-4819-123-7-199510010-00008.
To quantify the protective efficacy of influenza vaccine in elderly persons.
A MEDLINE search was done using the index terms influenza vaccine, vaccine efficacy, elderly, mortality, hospitalized, and pneumonia. Appropriate references in the initially selected articles were also reviewed.
Only cohort observational studies with mortality assessment were included in the meta-analysis. In addition, 3 recent case-control studies, 2 cost-effectiveness studies, and 1 randomized, double-blind, placebo-controlled trial were reviewed.
Vaccine and epidemic virus strains, age and sex of patients, severity of illness, patient status, and study design were recorded. Upper respiratory illness, hospitalization, pneumonia, and mortality were used as outcome measures.
In a meta-analysis of 20 cohort studies, the pooled estimates of vaccine efficacy (1-odds ratio) were 56% (95% Cl, 39% to 68%) for preventing respiratory illness, 53% (Cl, 35% to 66%) for preventing pneumonia, 50% (Cl, 28% to 65%) for preventing hospitalization, and 68% (Cl, 56% to 76%) for preventing death. Vaccine efficacy in the case-control studies ranged from 32% to 45% for preventing hospitalization for pneumonia, from 31% to 65% for preventing hospital deaths from pneumonia and influenza, from 43% to 50% for preventing hospital deaths from all respiratory conditions, and from 27% to 30% for preventing deaths from all causes. The randomized, double-blind, placebo-controlled trial showed a 50% or greater reduction in influenza-related illness. Recent cost-effectiveness studies confirm the efficacy of influenza vaccine in reducing influenza-related morbidity and mortality and show that vaccine provides important cost savings per year per vaccinated person.
Despite the paucity of randomized trials, many studies confirm that influenza vaccine reduces the risks for pneumonia, hospitalization, and death in elderly persons during an influenza epidemic if the vaccine strain is identical or similar to the epidemic strain. Influenza immunization is an indispensable part of the care of persons 65 years of age and older. Annual vaccine administration requires the attention of all physicians and public health organizations.
量化流感疫苗对老年人的保护效力。
使用索引词流感疫苗、疫苗效力、老年人、死亡率、住院、肺炎在MEDLINE数据库进行检索。对最初选定文章中的相关参考文献也进行了查阅。
荟萃分析仅纳入有死亡率评估的队列观察性研究。此外,还查阅了3项近期的病例对照研究、2项成本效益研究以及1项随机双盲安慰剂对照试验。
记录疫苗和流行病毒株、患者的年龄和性别、疾病严重程度、患者状态以及研究设计。将上呼吸道疾病、住院、肺炎和死亡率用作结局指标。
在对20项队列研究的荟萃分析中,预防呼吸道疾病的疫苗效力(1 - 比值比)合并估计值为56%(95%可信区间,39%至68%),预防肺炎为53%(可信区间,35%至66%),预防住院为50%(可信区间,28%至65%),预防死亡为68%(可信区间,56%至76%)。病例对照研究中,预防肺炎住院的疫苗效力为32%至45%,预防肺炎和流感导致的医院死亡为31%至65%,预防所有呼吸道疾病导致的医院死亡为43%至50%,预防所有原因导致的死亡为27%至30%。随机双盲安慰剂对照试验显示与流感相关疾病减少50%或更多。近期的成本效益研究证实流感疫苗在降低流感相关发病率和死亡率方面的效力,并表明疫苗可为每位接种者每年节省大量成本。
尽管随机试验较少,但许多研究证实,如果疫苗株与流行株相同或相似,流感疫苗可降低老年人在流感流行期间患肺炎、住院和死亡的风险。流感免疫是65岁及以上人群护理中不可或缺的一部分。每年接种疫苗需要所有医生和公共卫生组织的关注。